Pliant Therapeutics Inc (PLRX)
$12.52
Insights on Pliant Therapeutics Inc
Increasing Revenue
Revenue is up for the last 2 quarters, 248.0K → 4.83M (in $), with an average increase of 94.9% per quarter
Increasing Net Profit
Netprofit is up for the last 2 quarters, -41.48M → -41.10M (in $), with an average increase of 0.9% per quarter
Vs NVO
In the last 1 year, Novo Nordisk A/s has given 45.1% return, outperforming this stock by 103.6%
Vs NVO
In the last 3 years, Novo Nordisk A/s has given 238.3% return, outperforming this stock by 296.1%
Performance
- $12.52$12.88$12.52
0.04%
Downside
Day's Volatility :2.83%
Upside
2.8%
- $12.00$30.85$12.52
4.15%
Downside
52 Weeks Volatility :61.1%
Upside
59.42%
Returns
| Period | Pliant Therapeutics Inc | Sector (Health Care) | Index (Russel 2000) |
|---|---|---|---|
3 Months | -27.75% | -0.4% | 0.0% |
6 Months | -6.32% | 9.6% | 0.0% |
1 Year | -58.77% | 3.9% | -1.3% |
3 Years | -57.82% | 12.8% | -22.1% |
Highlights
Market Capitalization | 754.2M |
Book Value | $7.9 |
Earnings Per Share (EPS) | -2.75 |
Wall Street Target Price | 41.54 |
Profit Margin | 0.0% |
Operating Margin TTM | -11654.75% |
Return On Assets TTM | -26.68% |
Return On Equity TTM | -41.01% |
Revenue TTM | 1.6M |
Revenue Per Share TTM | 0.03 |
Quarterly Revenue Growth YOY | -100.0% |
Gross Profit TTM | 9.7M |
EBITDA | -182.3M |
Diluted Eps TTM | -2.75 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -3.28 |
EPS Estimate Next Year | -3.47 |
EPS Estimate Current Quarter | -0.81 |
EPS Estimate Next Quarter | -0.82 |
Analyst Recommendation
- Current
- 1M Ago
- 3M Ago
Analyst Forecast
What analysts predicted
Upside of 231.79%
Technicals Summary
Sell
Neutral
Buy
Pliant Therapeutics Inc is currently in a neutral trading position according to technical analysis indicators.
Peers
| Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
|---|---|---|---|---|---|
 Pliant Therapeutics Inc | -12.26% | -6.32% | -58.77% | -57.82% | -40.85% |
 Moderna, Inc. | -5.36% | 32.83% | -24.38% | -39.84% | 322.91% |
 Regeneron Pharmaceuticals, Inc. | -6.34% | 13.15% | 12.94% | 84.22% | 161.57% |
 Novo Nordisk A/s | -2.94% | 28.97% | 46.95% | 238.27% | 414.84% |
 Vertex Pharmaceuticals Incorporated | -3.87% | 8.77% | 20.15% | 83.53% | 128.04% |
| Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
|---|---|---|---|---|---|---|---|---|
Pliant Therapeutics Inc | NA | NA | NA | -3.28 | -0.41 | -0.27 | NA | 7.9 |
Moderna, Inc. | 24.73 | NA | 0.0 | -7.22 | -0.29 | -0.12 | NA | 36.27 |
Regeneron Pharmaceuticals, Inc. | 25.77 | 25.77 | 1.46 | 45.22 | 0.16 | 0.08 | NA | 242.47 |
Novo Nordisk A/s | 46.13 | 46.13 | 2.4 | 3.33 | 0.88 | 0.23 | 0.01 | 23.9 |
Vertex Pharmaceuticals Incorporated | 28.39 | 28.39 | 0.53 | 16.72 | 0.23 | 0.13 | NA | 68.22 |
| Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
|---|---|---|---|---|---|
Pliant Therapeutics Inc | Buy | $754.2M | -40.85% | NA | 0.0% |
Moderna, Inc. | Buy | $38.8B | 322.91% | 24.73 | -68.84% |
Regeneron Pharmaceuticals, Inc. | Buy | $98.4B | 161.57% | 25.77 | 30.14% |
Novo Nordisk A/s | Buy | $551.3B | 414.84% | 46.13 | 36.03% |
Vertex Pharmaceuticals Incorporated | Buy | $101.9B | 128.04% | 28.39 | 36.68% |
Institutional Holdings
Deep Track Capital, LP
9.55%BlackRock Inc
7.97%FMR Inc
6.58%T. Rowe Price Associates, Inc.
6.28%First Light Asset Management, LLC
5.96%LAURION CAPITAL MANAGEMENT LP
5.29%
Corporate Announcements
Pliant Therapeutics Inc Earnings
Pliant Therapeutics Inc’s price-to-earnings ratio stands at None
Read More
Company Information
pliant therapeutics is focused on discovering, developing and commercializing breakthrough treatments for fibrotic diseases. by harnessing the therapeutic potential of integrin biology and tgf-β modulation, pliant aims to prevent or even reverse fibrosis to address the needs of many patients. the company also aims to build a patient registry for certain areas of fibrotic disease to both increase understanding of natural disease progression, and fuel biomarker discovery. pliant’s co-founders include world-renowned researchers from university of california, san francisco (ucsf), who bring broad experience in fibrosis biology and small molecule chemistry. together, the pliant team is dedicated to translating scientific advances in fibrosis biology into novel therapies for patients in need.
Organization | Pliant Therapeutics Inc |
Employees | 158 |
CEO | Dr. Bernard Coulie M.B.A., M.D., Ph.D. |
Industry | Health Technology |
